Compared with ET, pre‐PMF patients had higher JAK2 V617F (p < 0.0001) and CALR (p = 0.025) mutant levels and more frequent ASXL1 mutations (p = 0.009). The gene discussed is ASXL1; the disease is essential thrombocythemia.